AstraZeneca said results from clinical trials showed that a drug to treat patients with anaemia from chronic kidney disease had significantly increased red haemoglobin levels. The so-called Olympus trial compared AstraZeneca's roxadustat to placebo while the Rockies trial compared the drug to epoetin alfa. 'Anaemia is a common, serious condition among patients with chronic kidney disease,' said Mene Pangalos, executive vice president, BioPharmaceuticals R&D. 'It occurs when the body has fewer healthy red blood cells than normal and low levels of haemoglobin, which may leave patients fatigued and short of breath.' 'Results from olympus and rockies reinforce the potential role that roxadustat could play in increasing haemoglobin levels and managing anaemia, which is often underdiagnosed and undertreated.'
Sign up to our
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
UK 350 Risers and Fallers
Tweets not available.